Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.14% ...
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ... Following this news, the price of Cassava's common ...
Stocktwits on MSN18d
Cassava Sciences Stock Craters After Alzheimer’s Disease Trial Flops: Retail’s DevastatedCassava Sciences Inc. ($SAVA) saw its stock plummet over 80% pre-market on Monday following the failure of a pivotal Phase 3 ...
In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $154.92 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study ...
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Zacks.com on MSN17d
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage StudyCassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback